Johnson Financial Group Inc. Takes Position in Stryker Corporation $SYK

Johnson Financial Group Inc. bought a new stake in shares of Stryker Corporation (NYSE:SYK) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 2,668 shares of the medical technology company’s stock, valued at approximately $842,000.

Other hedge funds have also made changes to their positions in the company. Gables Capital Management Inc. acquired a new position in Stryker during the 2nd quarter worth $25,000. Godfrey Financial Associates Inc. bought a new position in shares of Stryker during the fourth quarter valued at approximately $26,000. Sankala Group LLC acquired a new stake in Stryker in the fourth quarter worth $26,000. United Financial Planning Group LLC acquired a new stake in shares of Stryker in the 3rd quarter worth about $27,000. Finally, Atlas Capital Advisors Inc. acquired a new stake in shares of Stryker in the fourth quarter valued at approximately $27,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Ratings Changes

SYK has been the topic of a number of recent analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of Stryker in a research note on Friday, July 31st. BMO Capital Markets began coverage on Stryker in a research report on Wednesday, July 8th. They set an “outperform” rating and a $369.00 price objective for the company. Deutsche Bank Aktiengesellschaft set a $315.00 target price on shares of Stryker in a report on Friday, May 1st. Sanford C. Bernstein set a $410.00 target price on Stryker in a research report on Friday, May 1st. Finally, Leerink Partners lowered their price objective on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research report on Friday, June 5th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $386.28.

Insider Transactions at Stryker

In other news, insider Debra King sold 826 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. This represents a 11.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director directly owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 315,370 shares of company stock worth $98,463,501. 4.60% of the stock is currently owned by company insiders.

Stryker Trading Up 2.7%

Shares of SYK stock opened at $340.20 on Thursday. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.86. The business’s 50 day moving average is $326.19 and its two-hundred day moving average is $332.95. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The company has a market cap of $130.49 billion, a PE ratio of 35.25, a price-to-earnings-growth ratio of 2.11 and a beta of 0.76.

Stryker (NYSE:SYK) last released its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. During the same quarter in the previous year, the business earned $3.13 EPS. The business’s revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts predict that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. Stryker’s payout ratio is 36.48%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.